{
    "medicine_id": "aba0014d96a272ac63d73834b99d1a6d9335d81b",
    "platform_id": "DB05487",
    "metadata": {
        "name": "Adult Formula 50 60 61 v v Solution",
        "composition": "60 61 v v Custirsen",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in brain cancer and breast cancer",
            "contraindications": {
                "disease": "safe and well tolerated in a Phase I trial in healthy human volunteers",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "CC 8490 a new anti cancer compound from Celgene s proprietary class of benzopyrans being evaluated as a potential therapy for brain cancer The National Cancer Institute also reports applications in breast cancer related to potential antineoplastic activity CC 8490 acts as a selective estrogen receptor modulator SERM inhibiting the proliferation of estrogen sensitive breast cancer cells This agent also inhibits growth and induces apoptosis of glioblastoma cells via a mechanism independent of estrogen receptor related mechanisms",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}